Sasine Joshua P, Schiller Gary J
UCLA Department of Medicine, Division of Hematology and Oncology, Orthopedic Hospital Research Center/BSRB, 615 Charles E. Young Drive South, Room 545, Los Angeles, CA, 90095, USA.
UCLA Department of Medicine, Division of Hematology and Oncology, Aramont Foundation for Clinical/Translational Research in Human Malignancies, Room 42-121 Center for Health Sciences, David Geffen School of Medicine at UCLA, Los Angeles, 90095, CA, USA.
Curr Hematol Malig Rep. 2016 Dec;11(6):528-536. doi: 10.1007/s11899-016-0346-x.
The development and approval of novel, effective therapies for acute myeloid leukemia (AML) has lagged behind other malignancies. Judging success of therapy with meaningful endpoints is critical to development of new treatments. Overall survival (OS) has typically been the parameter necessary for regulatory approval of experimental therapy in AML. Herein, we discuss different strategies to define outcomes for patients with AML and their relative challenges.
急性髓系白血病（AML）新型有效疗法的研发和获批一直落后于其他恶性肿瘤。采用有意义的终点指标来评判治疗效果对于新疗法的研发至关重要。总生存期（OS）通常是AML实验性疗法获得监管批准所需的参数。在此，我们讨论定义AML患者治疗结局的不同策略及其相对挑战。
